Percutaneous image-guided thermal ablation is safe and efficacious in achieving local control and improving outcome in the treatment of both early stage nonesmall-cell lung cancer and pulmonary metastatic disease, in which surgical treatment is precluded by comorbidity, poor cardiorespiratory reserve, or unfavorable disease distribution. Radiofrequency ablation is the most established technology, but new thermal ablation technologies such as microwave ablation and cryoablation may offer some advantages. The use of advanced techniques, such as induced pneumothorax and the popsicle stick technique, or combining thermal ablation with radiotherapy, widens the treatment options available to the multidisciplinary team. The intent of this article is to provide the reader with a practical knowledge base of pulmonary ablation by concentrating on indications, techniques, and follow-up.
Primary lung cancer is the leading cause of cancer deaths in men and women, and accounts for approximately 29% of all cancer deaths [1] . Despite significant advances in medical and surgical treatment, the prognosis of primary lung cancer remains poor; the strong association with other smokingrelated comorbidities means that many patients are not candidates for surgical resection. This has resulted in new chemoradiation regimens (including stereotactic beam radiotherapy) and has fuelled the search for novel, minimally invasive therapies, including thermal ablation.
Image-guided ablation involves the percutaneous insertion of an ablation needle (electrode, antenna, or probe) directly into a tumour under image guidance (most commonly computer tomography [CT] ) and subsequent manipulation of the thermal environment within and immediately surrounding the tumour, which results in cell lysis, apoptosis, or desiccation. In addition to nonsurgically resectable primary lung neoplasia, this technique has also expanded the treatment options for patients with pulmonary metastases, particularly for those who are poor surgical candidates [2] . The intent of this article is to provide the reader with a practical knowledge base of pulmonary ablation, concentrating on indications, techniques, and follow-up. The reader is encouraged to explore more-detailed aspects of comparative outcomes to better understand the context in which these techniques exist within the spectrum of care.
Background
The prognosis of primary lung cancer remains poor, with a 5-year survival of just 15% [1] . The prognosis and treatment depend on the histologic type of tumour (small-cell lung cancer [SCLC] vs nonesmall-cell lung cancer [NSCLC] ), the clinical stage at presentation, and the patient's cardiorespiratory function [3] .
Surgical resection remains the standard of care for early stage NSCLC and offers the most favorable outcome [3] . When possible, lobectomy is preferred to smaller wedge resections, which have been shown to result in a higher incidence of local recurrence and reduced long-term survival [4, 5] . The 5-year survival rates of resected stage I and II disease are reasonable (75% and 60%, respectively), but, unfortunately, only approximately 5% of patients present with both early stage disease and meet the pulmonary physiologic guidelines to undergo resection [5] . The great majority of patients with SCLC are treated with chemotherapy; surgical intervention is reserved for those few individuals with localized stage I disease.
Minimally invasive surgical techniques, for example, video-assisted thoracoscopic surgery have revolutionized the ability to perform curative surgery on historically nonsurgical candidates. Complementary interventional radiologic techniques, for example, fuzzy wire localization, have contributed to the safety and efficacy of these procedures [6] . However, many patients remain poor surgical candidates due to compromised lung function or other comorbidities [7] . External-beam radiotherapy, with or without chemotherapy, may be considered when poor pulmonary function precludes resection, but published outcomes are inferior to surgery [8] . Significant adverse effects may also be encountered with external-beam radiotherapy, which may result in morbidity (including radiation pneumonitis, esophagitis, skin burns, and oropharyngeal mucosal sloughing) or even mortality [2] .
Within the context of nonlung primary neoplasia, the lung represents the second most common organ location of metastatic disease; unfortunately, many patients with lung metastases also present with extrapulmonary disease and may, therefore, not be candidates for treatment with curative intent, although cytoreductive and/or palliative therapy may be indicated. Pulmonary metastases are typically peripheral and have a predilection for the lung bases, and, therefore, are often easily targeted for image-guided localization, biopsy, and percutaneous ablation. A peripheral location also means that many metastases are amenable to video-assisted thoracoscopic surgery resection or open metastasectomy, although segmentectomy or lobectomy may be indicated, depending on the distribution of the disease. Disease distributed within multiple lobes may be difficult or impossible to resect but may be amenable to thermal ablation [9] ; therefore, all potential surgical or ablation targets (primary and secondary tumours) should ideally be reviewed and discussed in the setting of a multidisciplinary team. When poor pulmonary function or disease distribution preclude resection, or when chemotherapy or radiotherapy have failed, percutaneous thermal ablation can offer an alternative approach [2] .
Technology and Techniques

Radiofrequency Ablation
The term radiofrequency (RF) describes all electromagnetic energy sources with frequencies lower than 30 MHz, but most probes in current use operate around the order of 3-500 kHz. RF ablation (RFA) is well established in the treatment of solid organ tumours, and, since the turn of the century, this technology has shown promise as a minimally invasive and efficacious treatment platform within the lung. Pulmonary RFA was first described in a rabbit lung model in 1995 [10] , and the first treatment in human lungs was reported by Dupuy et al [11] in 2000.
There are 2 varieties of RF electrodes available, those with tines and those without [12] . Tines are small wires deployed from within the electrode, once a suitable electrode position is achieved within the lesion under image guidance; the deployed tines either point forward (RITA System; RITA Medical Systems, Fremont, CA) or curve back towards the hub (LeVeen Electrode; Boston Scientific Corp, Marlborough, MA). The nontine systems (eg, Covidien Cool-tip; Covidien, Mansfield, MA) consist of forward-oriented electrodes, deployed singularly or as a cluster array ( Figure 1 ). The electrodes are cooled internally, often by an ice-cold saline solution pump, which prevents charring at the needle tip, which would otherwise impede the circuit and reduce the ablation zone.
Once inserted under image guidance (typically CT), the electrode is attached to a generator and the electrical circuit is completed through the patient by using grounding pads, usually placed on the thighs. The generator produces an alternating current that passes through the patient; the oscillating current causes collisions of electrons within molecules close to the electrode, which produces friction and heat [13] . The tissue is heated to temperatures higher than 60 C, which results in cell death [14] ; the ablation zone aims to encompass the entire lesion with a safety rim of normal parenchyma (ideally of up to 10 mm).
RFA remains the most widely used thermal ablation technology within the lung. However, the application of RF as an ablative energy within the lung parenchyma is beset by a number of technical challenges. Although the aerated adjacent lung provides insulation, which concentrates energy within the ablation zone and protects the normal parenchyma, the challenge of lung RFA is in overcoming the high impedance and poor conductivity created by the same aerated parenchyma and the heat sink effect of blood and air flow through the lung, while also requiring a lower electron flux to develop an adequate target temperature without causing charring at the electrode tip (typically in the 60 W range). Technical limitations such as these, together with an ambition to perform larger, more efficacious, and safer percutaneous ablations has led to the exploration of alternative thermal ablation technologies.
Microwave Ablation
The microwave (MW) spectrum describes electromagnetic energy of 300 MHz to 300 GHz, and clinical MW ablation (MWA) systems operate at frequencies in the order of 1-2000 MHz (1-2 GHz). Unlike RFA, the reduced impedance of aerated lung or charred tissue does not limit MWA, which deposits energy more quickly in a broader zone around the antenna [13] . There are a number of MWA systems available, most use insulated hollow antennae perfused with either fluid or carbon dioxide, to reduce heating of the needle shaft, which would otherwise burn the skin and subcutaneous tissues. Once inserted within the target lesion and attached to an MW generator, the application of MW energy results in the rapid spinning of polarized water molecules, which rotate to align within the alternating field polarity. The spinning water molecules accumulate kinetic energy, which heat the tissue [13] .
MWA offers a number of practical advantages over RFA; in particular, MWA can result in the faster treatment of a larger volume of tissue at higher temperatures [15] and with less ''heat sink'' effect than is associated with RFA. The larger zone of active heating often removes the need for the deployment of multiple antennae, and grounding pads are not required.
Laser Ablation
Laser ablation involves heating tissue via interactions with laser photons (eg, neodymium:yttrium-aluminumgarnet laser, wavelength 1064 nm). Photons are delivered via a cooled fiberoptic cable introduced through an outer needle-like sheath, which is inserted under image guidance. Ablation zones can be limited by charring, and treatment often requires the application of multiple fibers. It is a technique in relative infancy but one that has shown promise in the treatment of pulmonary malignancy [16] .
Cryoablation
The original cryoablation probes used liquid nitrogen to cool, but this technology has been superseded by the use of argon cooling systems, which can achieve cooling to temperatures as low as À140 C via the Joule-Thomson effect. Cooling to sub À40 C results in tissue death via cell rupture, protein denaturation, osmotic shifts, and microvascular thrombosis and infarction [13, 17] . Typically, a freeze-thaw-freeze cycle is used to treat lesions. The probes tend to be of smaller gauge than RFA electrodes or MWA antennae but so is the ablation zone, and multiple probes are often required to treat larger lesions. Visualization on CT of the ice ball confers some advantages by allowing control over the ablation zone, to achieve an adequate margin, or to avoid an adjacent vessel; however, the zone of cell death is smaller than the visible ice ball. Some systems have a freezestick mode, which allows fixation of a probe within a lesion before maneuvering it away from a critical structure (see popsicle stick technique below).
Combined Thermal Ablation and Radiotherapy
Multimodality treatment aims to increase the potential for tumour cell death, while limiting the risk of adverse effects and the likelihood of residuum or recurrence; it is a field of great promise. The synergistic effect of chemotherapy and thermal injury is established and the subject of ongoing research [13] . The theoretically complementary effects of radiotherapy and thermal ablation are intriguing; radiotherapy is less effective at the hypoxic core of a lesion, whereas thermal ablation will have maximal efficacy, whereas at the neovascularized margin, radiotherapy is more effective and will reduce the risk of local recurrence [13] .
The results of a recent study by Grieco et al [18] suggest that combining external-beam radiotherapy or high-dose iridium brachytherapy with thermal ablation of stage I or II NSCLC may result in improved survival, with a low rate of complications [18] . On a practical level, fiducial placement at the time of ablation is also possible by using a coaxial technique, which facilitates the targeting of postablative external-beam radiotherapy.
Indications
The patients selected for thermal ablation generally fall into 1 of 2 categories: those undergoing treatment with curative intent and those requiring palliation, and both categories include those patients who refuse surgery, radiotherapy, or alternative treatment options. The former category is of patients with primary or secondary tumours, who are not surgical candidates, either because of insufficient cardiorespiratory reserve to tolerate resection or preclusive comorbidity. The latter category is a palliative group in which the patients might require treatment because of painful chest wall or brachial plexus involvement, tumour recurrence not suitable for further radiotherapy or surgery, or, rarely, hemoptysis [13, 19] .
The standard of care for stage I NSCLC is, and will remain, surgical resection [1] . Patients with medically inoperable disease should be offered either stereotactic radiation therapy or RFA according to the American College of Chest Physicians guidelines (2007) [20] . In some patients with more-advanced stage disease, thermal ablation may also represent a reasonable treatment option; for example, those with stage IIIb disease due to a second nodule within the same lobe, or stage IV disease based on a satellite nodule within another lobe [21] . Thermal ablation may be used in the salvage scenario to control a patient with a persistent or recurrent solitary disease focus despite radiotherapy, chemotherapy, or surgery [21] . Thermal ablation has been used in conjunction with radiotherapy in patients with stage I or II NSCLC; there are new data that suggest that the outcome of combined treatment may be more favorable than with either modality alone [18] .
Currently, thermal ablation is offered to patients with a limited number of metastases that are inoperable, either due to tumour distribution, a lack of cardiopulmonary reserve, or patient comorbidity, or those who decline surgery. Ideally, patients will have oligometastatic disease, with 5 or fewer lesions and in whom there is a realistic prospect of treating with curative intent or at least achieving sustained disease control. Most centres will treat such patients who have up to 5 or 6 lesions, but some operators will take on more [9] . Thermal ablation has been used to treat pulmonary metastases of various primary sources, including colorectal, renal cell, hepatocellular, and breast carcinoma; sarcoma; and melanoma [13, 22] . It is not clear that tumour biology significantly influences the local control rate [23] , but tumour biology does affect overall survival and, therefore, remains of significant influence in patient selection [24] . Tumour size is crucial, with treatment of lesions smaller than 3.5 cm resulting in much improved local control [22] . Ideally, lesions are at least 1 cm from a major vessel, airway, or esophagus, although, with advanced techniques, for example, induced pneumothorax, these unfavorable anatomic circumstances can be overcome. Thermal ablation is also useful in the treatment of patients with recurrent metastatic disease after previous thoracotomy, in which the morbidity associated with a repeated thoracotomy can be avoided [21] .
The optimal lesion characteristics and conditions are 3 or fewer lesions of up to 3.5 cm, at least 1 cm from critical structures. In general, a patient fit enough to undergo needle biopsy of the thorax is fit enough to undergo ablation. An unmanageable coagulopathy represents the only absolute contraindication [21] .
Workup
The patient should ideally be reviewed at a multidisciplinary meeting, all treatment options should be explored, and the appropriateness and goal (curative or palliative) of thermal ablation established; a recent CT is required to plan the procedure. Positron emission tomographyeCT (PET-CT) is useful in planning the treatment of tumours that are fluorodeoxyglucose avid and is becoming the standard of care for pretreatment staging and follow-up but has its own limitations (eg, lesion size) and is known to underestimate disease (particularly hilar and mediastinal nodal metastases) as evaluated by surgical methods, which remain the criterion standard.
Anticoagulant and antiplatelet medication should be discontinued and coagulation parameters should be within reasonable limits (international normalized ratio < 1.5). Some, but not all, operators administer antibiotic prophylaxis to reduce the incidence of abscess formation. RFA may result in pacemaker resetting during the procedure, and both pacemakers and implanted defibrillators should be managed by a cardiologist and do not preclude ablation [25] . Pacemaker leads do not heat sufficiently due to dissipation and if required, external pacing can be performed [26] .
Basic Setup
The following paragraph outlines some practical aspects of the general approach to pulmonary ablation used at our institution, and it is important to note that practice varies greatly among operators and centres, and there is no single correct strategy or technique defined in the literature.
The procedure is typically performed with the patient under light conscious sedation, but, if required, general anesthesia is a reasonable alternative and occasionally advantageous (eg, allowing accurate and consistent cessation of respiration during targeting). The practical setup and operator approach to pulmonary ablation is often challenging; factors that require consideration include the size, shape, and location of the lesion; the route to the lesion (avoiding vital structures, minimizing the crossing of fissures); and specific characteristics of the ablative technique (size and shape of the ablation zone, the need for multiple electrodes and/or probes, etc). The patient is positioned supine, prone, or on the side to allow the least traumatic and most ergonomically feasible percutaneous route to the lesion. A suitable skin puncture location is determined with the aid of a grid and local anesthesia is injected to the skin and pleura. The thermal ablation device is then introduced to the lesion under CT guidance; if available, CT fluoroscopy can facilitate targeting. A tandem needle approach is occasionally used, by which the lesion is initially located with a fine bore (eg, 22 gauge) needle, which can be used to instill peripleural local anaesthetic; this needle then acts as a guide for the parallel insertion of the ablation probe. For subpleural lesions, the ablation probe can be introduced under direct ultrasound visualization, in which case a linear transducer is favored. A chest tube kit is kept on standby in case rapid decompression of a pneumothorax is required.
Advanced Techniques
Iatrogenic Pneumothorax
Where a lesion abuts a critical structure, such as a great vessel, the esophagus, cardiac border, or phrenic nerve, the introduction of a pneumothorax can displace the lesion away from the critical structure, reducing the risk of thermal injury (Figure 2 ). In the case of RFA, this can also reduce the heat sink during the treatment of a lesion adjacent to a major vessel. This effect is borne out in results from Iguchi et al [27] who compared local control rates of RFA of lesions abutting the heart or great vessels, with control rates of treated lesions close (1-9 mm) to those structures, and found significantly improved control rates in the latter group.
The pneumothorax is created with the injection of air into the pleural space; this can be readily achieved with the CTguided insertion of a micropuncture access sheath and introduction of a small pigtail catheter over a 0.035-inch wire. The volume of gas within the pleural space is controlled by using a 60-mL Leuer lock syringe attached to the drain.
Popsicle Stick Technique
Some cryoablation systems allow a freeze-stick mode, which enables the probe to be inserted within the lesion, then fixed within it by freezing the immediately adjacent tissue without ablating a wider zone. Once fixed, the lesion can be manually steered away from a critical structure before the treatment cycle is initiated, typically after the introduction of an iatrogenic pneumothorax ( Figure 2 ).
Stacked Ablation Technique, Cluster Technique, and the Cluster Array Needle
In the absence of alternative therapeutic options, large and nonspherical lesions can be treated with percutaneous thermal ablation either by stacking adjacent ablation zones or by using a cluster array needle (Figure 1) or multiple adjacent needles (the cluster technique) to sculpt the ablation zone contour to fit the lesion profile. These techniques can be used either sequentially or together in tandem (Figure 3 ).
Fluid Instillation for the Treatment of Cavitatory Lesions
The treatment of air-filled cavitatory or cystic lesions within the lung can be challenging, due to the high impedance of the air-filled space. This can be overcome by instilling ionic fluid (normal or hypertonic saline solution) within the air-filled space before deployment of a RFA electrode (Figure 4) . The saline solution reduces impedance throughout the lesion, which results in a larger, more homogenous and efficacious ablation zone.
Postablation Imaging and Follow-up
The immediate postablation CT will reveal distorted tumour margins surrounded by concentric rims of altered attenuation, referred to as the cockade phenomenon [28] . This is typically ground-glass density and resolves within 1-3 months [13] . The finding of a rim of ground glass immediately after ablation is an encouraging sign and presumed to represent the zone of coagulative necrosis, analogous to the surgical margin ( Figure 5 ) [2, 29] .
Long-term follow-up is required to allow the early detection of recurrent disease when re-treatment is ideally Figure 2 . The popsicle stick technique. The lesion has been targeted with a cryoprobe and freeze-stick mode activated (A). An iatrogenic pneumothorax was then created (B), and, with leverage on the cryoprobe, the lesion was steered away from the adjacent right heart border before the treatment cycle was initiated (C).
instituted. After thermal ablation, the ablation defect and lesion are indistinguishable on CT, and it is vital for the radiologist reporting follow-up imaging to appreciate that the apparent lesion size within the first 6 months is very variable; in fact, the posttreatment defect often appears larger than the pretreatment lesion. A transient increase in size at 1 month is seen in the majority of cases and can persist for up to 6 months ( Figure 6 ) [30] . Cavitation and pleural changes are frequently observed within the first 3 months [30] , and reactive adenopathy is also commonly observed. Lesion growth beyond 6 months is a worrisome finding and suggestive of local recurrence [13] . A reduction in the mean contrast enhancement of successfully treated lesions is seen at 1-2 months but is a less reliable finding after this period, presumably due to the presence of enhancing perilesional granulation tissue [13, 31] .
Functional imaging with PET-CT has become the preferred follow-up modality and offers some considerable advantages (Figure 7) . For example, PET-CT has been shown to predict tumour regrowth earlier than CT, with an absence of fluorodeoxyglucose activity frequently seen at 1 month [32] . However, the limitations inherent within the technique must be taken into account, with false-positive results due to postablative granulation tissue or inflammatory change. PET-CT imaging at 3-6 months results in fewer false-positive results [33] .
Complications
Pneumothorax is the most frequent complication of thermal ablation, due to the relatively large needle gauge and frequent underlying emphysema; reported rates vary widely (rates of 10%-35% are most frequently described) [13] . A small minority of pneumothoraces (approximately 10%) will require chest-tube placement, and most are removed at 24 hours [13] .
Periprocedural pain is generally well controlled with intravenous opioid and anxiolytics; the instillation of peripleural long-acting local anaesthetic may also be of benefit. A mild fever can last for up to a week and a productive cough can last for a few weeks more. Mild hemoptysis and pneumonia are occasionally encountered; bronchopulmonary fistula and abscess formation are rare. Massive bleeding is very rare. Thermal injury to large vascular structures is rarely encountered due to heat sink. Phrenic nerve injury is well described, but the risk is reduced by appreciation of the relevant anatomy (it courses adjacent to the superior vena cava) and techniques such as induced pneumothorax [34, 35] .
Outcomes
Most of the current literature consists of a series from single institutions and is comprehensively covered elsewhere [13]; the key publications will be reviewed in brief, and it is important to note that the published data are far less substantial than the surgical literature. A multicentre study (Response to Radiofrequency Ablation of Pulmonary Tumours: A Prospective, Intention-to-Treat, Multicentre Clinical Trial [RAPTURE]) published by Lencioni et al [24] included 106 patients with NSCLC and metastases. The 3-year survival after RFA was 48%, although most patients were at high risk and died of noncancer-related causes; the 2-year cancer-specific survival rate was 92% [24] . Simon et al [36] published a study of a cohort of 153 patients (NSCLC and metastases); overall survival was 78% at 1 year and 27% at 5 years. Their data confirmed the improved outcomes after the treatment of lesions of 3 cm and smaller [36] . A single-arm phase II prospective pilot trial of thermal ablation (funded by the National Cancer Institute and run through the American College of Surgeons of Oncology Group, across 25 institutions) will examine 2-year survival and local control in patients with stage IA medically inoperable NSCLC will be published this year, and results are eagerly awaited.
There are limited data regarding MWA, with a single series published in the English language literature. Wolf et al [37] published a series of 50 patients undergoing a total of 66 MW ablations of both (NSCLC and metastases), which reported a total local control rate of 80% at a median followup of 10 months. Again, they found significantly increased local recurrence rates for target lesions larger than 3 cm. The mean (SD) cancer-specific survival at 1 year was 83% AE 6% and at 3 years was 61% AE 13%.
Wang et al [38] reported a series of 187 patients undergoing cryoablation for primary and metastatic pulmonary malignancy. The short follow-up precluded any useful interpretation of local control or survival benefits; however, they demonstrated the feasibility and safety of pulmonary cryoablation and confirmed the palliative benefits of therapy, 
Conclusion
Percutaneous, image-guided thermal ablation techniques have a growing role in clinical practice for the treatment of primary and secondary malignancy in the lung, where surgical treatment is precluded by comorbidity, poor cardiorespiratory reserve, or disease distribution. RFA is the most-established technique, but new thermal ablation technologies, such as MW and cryoablation, offer some potential advantages over RFA. Thermal ablation has been to proven to be safe and efficacious in achieving local control and improving outcomes in the treatment of both early stage NSCL and metastatic disease. There are some data to suggest that combining thermal ablation and radiation may improve outcome over thermal ablation alone. By using advanced techniques, such as induced pneumothorax, cluster needle, and popsicle stick techniques, anatomically challenging lesions can be treated successfully.
